Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma DOI Creative Commons
Ying Lu, Zhouyu Wang,

Danmeng Zhang

et al.

Cellular and Molecular Neurobiology, Journal Year: 2024, Volume and Issue: 45(1)

Published: Dec. 18, 2024

Glioma is the most common primary malignant brain tumor. Despite significant advances in past decade understanding molecular pathogenesis of this tumor and exploring therapeutic strategies, prognosis patients with glioma remains poor. Accurate diagnosis very important for treatment prognosis. Although gold-standard method prediction tissue biopsy, it still has many limitations. Liquid biopsy can provide information on auxiliary gliomas. In review, we summarized application cell-free DNA (cfDNA) circulating (ctDNA) glioma. The methods used to detect ctDNA gliomas using samples including blood cerebrospinal fluid (CSF) detection techniques ctDNA, droplet digital PCR (ddPCR) next-generation sequencing (NGS), were discussed. Detection from plasma tumors challenging because blood–brain barrier (BBB). CSF been proposed as a medium analysis tumors, mutation was less sensitive than sequencing. Moreover, ongoing relevant clinical studies summarized. Finally, discussed challenges, future directions

Language: Английский

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives DOI Open Access

Francesca Carosi,

Elisabetta Broseghini,

Laura Fabbri

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(15), P. 2752 - 2752

Published: Aug. 2, 2024

The isocitrate dehydrogenase 1 and 2 (IDH1 IDH2) enzymes are involved in key metabolic processes human cells, regulating differentiation, proliferation, oxidative damage response. IDH mutations have been associated with tumor development progression various solid tumors such as glioma, cholangiocarcinoma, chondrosarcoma, other types become crucial markers molecular classification prognostic assessment. intratumoral serum levels of D-2-hydroxyglutarate (D-2-HG) could serve diagnostic biomarkers for identifying mutant (IDHmut) tumors. As a result, an increasing number clinical trials evaluating targeted treatments IDH1/IDH2 mutations. Recent studies shown that the focus these new therapeutic strategies is not only neomorphic activity IDHmut but also epigenetic shift induced by potential role combination treatments. Here, we provide overview current knowledge about tumors, particular on available IDH-targeted emerging results from aiming to explore tumor-specific features identify benefit therapies their strategies. An insight into future perspectives roles circulating radiomic included.

Language: Английский

Citations

9
liquid biopsy holds a promising approach for the early detection of cancer: Current information and future perspectives DOI
Abdullah M. Shbeer, Ibrahim Ahmed Robadi

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 254, P. 155082 - 155082

Published: Jan. 3, 2024

Language: Английский

Citations

3
Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements DOI
Ryan A. Sheikh, Salma Naqvi,

Ayman Mohammed Al-Sulami

et al.

CNS & Neurological Disorders - Drug Targets, Journal Year: 2024, Volume and Issue: 24(1), P. 74 - 82

Published: July 3, 2024

Background: Gliomas are the most frequent, heterogeneous group of tumors arising from glial cells, characterized by difficult monitoring, poor prognosis, and fatality. Tissue biopsy is an established procedure for tumor cell sampling that aids diagnosis, grading, prediction prognosis. Materials Methods: We studied compared levels liquid markers in patients with different grades glioma. Also, we tried to prove potential association between glioma specific blood antigens. Results: 78 were found, among whom maximum percentage glioblastoma had O+ (53.8%). The second highest frequency A+ (20.4%), followed B+ (9.0%) A- (5.1%), least O-. Liquid biomarkers included Alanine Aminotransferase (ALT), Lactate Dehydrogenase (LDH), lymphocytes, Urea, Alkaline phosphatase (AST), Neutrophils, C-Reactive Protein (CRP). all components increased significantly severity glioma, seen (grade IV), grade III II, respectively. Conclusion: have significant clinical challenges due their progression nature aggressive behavior. A a non-invasive approach setting up status patient figuring out grade; therefore, it may show diagnostic prognostic utility. Additionally, our study provides evidence role ABO antigens development However, future research on will improve sensitivity specificity these tests confirm usefulness guide treatment approaches.

Language: Английский

Citations

0
Biosensors and disease diagnostics in medical field DOI
Harpreet Kaur Channi,

Ramandeep Sandhu,

Deepika Ghai

et al.

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 25 - 42

Published: Oct. 4, 2024

Language: Английский

Citations

0
Liquid biopsy in diagnosis of central nervous system tumors DOI
Andrey Gavrjushin, A A Veselkov, Anatol Schmidt

et al.

Burdenko s Journal of Neurosurgery, Journal Year: 2024, Volume and Issue: 88(6), P. 110 - 110

Published: Jan. 1, 2024

Tumor tissue samples are necessary for histological diagnosis. Biopsy is associated with certain difficulties, especially in neuro-oncology. An alternative approach (liquid biopsy) currently being developed. The last one based on analysis of biological fluids regarding DNA tumors and other biomarkers. This less invasive diagnostic method may be valuable to overcome the disadvantages traditional biopsy.

Language: Английский

Citations

0
Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma DOI Creative Commons
Ying Lu, Zhouyu Wang,

Danmeng Zhang

et al.

Cellular and Molecular Neurobiology, Journal Year: 2024, Volume and Issue: 45(1)

Published: Dec. 18, 2024

Glioma is the most common primary malignant brain tumor. Despite significant advances in past decade understanding molecular pathogenesis of this tumor and exploring therapeutic strategies, prognosis patients with glioma remains poor. Accurate diagnosis very important for treatment prognosis. Although gold-standard method prediction tissue biopsy, it still has many limitations. Liquid biopsy can provide information on auxiliary gliomas. In review, we summarized application cell-free DNA (cfDNA) circulating (ctDNA) glioma. The methods used to detect ctDNA gliomas using samples including blood cerebrospinal fluid (CSF) detection techniques ctDNA, droplet digital PCR (ddPCR) next-generation sequencing (NGS), were discussed. Detection from plasma tumors challenging because blood–brain barrier (BBB). CSF been proposed as a medium analysis tumors, mutation was less sensitive than sequencing. Moreover, ongoing relevant clinical studies summarized. Finally, discussed challenges, future directions

Language: Английский

Citations

0